Sign Up Today and Learn More About Melt Pharmaceuticals Stock
Invest in or calculate the value of your shares in Melt Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Melt Pharmaceuticals Stock (MEPH)
Melt Pharmaceuticals focuses on developing novel approach to providing procedural sedation and analgesia for short-term medical procedures.
About Melt Pharmaceuticals Stock
Founded
2019
Headquarters
Needham, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Melt Pharmaceuticals Press Mentions
Stay in the know about the latest news on Melt Pharmaceuticals
Pharmaceutical compositions and methods for anesthesiological applications
patents • Apr 02, 2025
Midazolam and ketamine for enhanced sedation
patents • Feb 12, 2025
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
businesswire • Nov 20, 2024
HROW Aug 2024 20.000 put (HROW240816P00020000) Stock Price, News, Quote & History
finance • Aug 03, 2024
Pharmaceutical compositions and methods for anesthesiological applications
patents • Apr 14, 2024
Melt Pharmaceuticals Management
Leadership team at Melt Pharmaceuticals
Chief Financial Officer
Brad Osborne
Founder
Mark L. Baum
Join now and verify your accreditation status to gain access to:
- Melt Pharmaceuticals Current Valuation
- Melt Pharmaceuticals Stock Price
- Melt Pharmaceuticals Management
- Available deals in Melt Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Melt Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Melt Pharmaceuticals Revenue and Financials
- Melt Pharmaceuticals Highlights
- Melt Pharmaceuticals Business Model
- Melt Pharmaceuticals Risk Factors
- Melt Pharmaceuticals Research Report from SACRA Research
Trading Melt Pharmaceuticals Stock
How to invest in Melt Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Melt Pharmaceuticals through EquityZen funds. These investments are made available by existing Melt Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Melt Pharmaceuticals stock?
Shareholders can sell their Melt Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
